Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says

This article was originally published in The Pink Sheet Daily

Executive Summary

KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.


Related Content

DTC Price Comparisons To Get FDA Scrutiny
KV’s Suit Against FDA Is Revived By Thiopental Ruling, Compounding Law
KV Emerging From Bankruptcy As Makena Sales Pick Up Steam
Compounding Bill In Senate Adds Office Use Provisions
Rep. Griffith’s Compounding Draft Ties FDA Inspections To State Reporting
Orphan Drug Prices To Face Fiscal Cliff Scrutiny, NORD Expects
FDA Helps Makena With Statement Against High-Volume Compounding
Regulatory News, In Brief
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts